Poland is testing the world’s first mRNA lung cancer vaccine, offering a groundbreaking personalized treatment approach for patients.
Poland is at the forefront of a groundbreaking clinical trial testing the efficacy of the first mRNA vaccine for non-small cell lung cancer (NSCLC). Professor Dariusz M. Kowalski from the National Institute of Oncology in Warsaw confirmed the ongoing study, highlighting that patients are still being recruited.
Personalized Vaccine Development
The trial involves patients who have undergone radical surgery with the potential for a permanent cure. If a tumor biopsy confirms a specific clinical stage of the disease, patients receive standard adjuvant chemotherapy. Simultaneously, tumor tissue is sent to the U.S. for genetic analysis, where dozens of genes responsible for lung cancer progression are identified.
Tailored Treatment Approach
Based on this genetic profile, an mRNA vaccine is custom-developed for each patient. This vaccine is designed to train the immune system to recognize and destroy lung cancer cells, preventing future recurrence. Patients also receive immunotherapy as part of this personalized treatment.
Poland is one of seven countries, alongside the UK, Germany, Hungary, Spain, Turkey, and the USA, participating in this innovative study.